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Abstract
Background: Obsessive compulsive disorder (OCD) is a chronic mental health condition recognized as one of the
most serious causes of disability and impaired quality of life. In the literature, there is no review about sexual
dysfunction and satisfaction in OCD. The current paper presents the protocol for a systematic review and meta-
analysis aimed to summarize data (1) comparing the presence of sexual dysfunction between groups with OCD
and non-clinical groups, (2) investigating prevalence of each one of the sexual dysfunctions in patients with OCD,
(3) comparing risk for sexual dysfunction in OCD groups with the prevalence in control groups, (4) comparing
sexual satisfaction between OCD groups and non-clinical groups, and (5) investigating moderators of sexual
dysfunction in OCD groups as compared with control groups. Gender, age, marital status, OCD symptom severity
and subtypes, comorbid depressive disorders, comorbid anxiety disorders, concurrent psychiatric medications,
comorbid general medical disease, and study quality will be investigated as moderators.
Methods: The protocol is reported according to PRISMA-P guidelines. The search will be conducted by independent
reviewers during the second week of December 2019 by using electronic databases (Scopus, PubMed, EMBASE,
PsycINFO, CINAHL, and the Cochrane Library), by contacting the authors of the included studies to identify further data,
by examining the references of the included studies, and by handsearching conference proceedings and theses/
doctoral dissertations. The study quality will be independently evaluated using the Newcastle-Ottawa Quality
Assessment Scale. Random-effect meta-analyses will be computed. If there is insufficient data for a specific outcome,
only a systematic review will be performed.
Discussion: This review may support clinical practice highlighting the importance of the assessment of sexuality in
patients with OCD and suggesting the use of therapeutic strategies dedicated to sexuality in this clinical population
with the aim of improving patients’ quality of life. Potential limitations will regard the heterogeneity of the studies in
terms of the instruments used to assess sexual dysfunction/satisfaction and of the definitions used to conceptualize
sexual dysfunction.
Systematic review registration: Prospero CRD42019132264
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Background
Clinical picture and treatment challenges of OCD
Obsessive compulsive disorder (OCD) is a chronic mental
health condition characterized by recurrent unwanted
thoughts, impulses, or mental images called obsessions,
accompanied by repetitive behaviours called compulsions
[1]. While obsessions provoke unpleasant emotions in-
cluding anxiety, disgust, or guilt, compulsions are repeti-
tively performed to cope with the unpleasant feelings
evoked by the former, although relief is often only tem-
porary [1]. This condition has a 2–3% lifetime prevalence
and an equal gender distribution in the general population
[2]; age at onset follows a bimodal distribution with one
peak arising in childhood or early adolescence and an-
other in late adolescence or early adulthood [3].
Amongst all psychiatric disorders, OCD is recognized as
one of the most serious causes of disability and impaired
quality of life in family and social relationships [4–8], and
it is associated with considerable economic costs to the
individual, healthcare services, and informal caregivers [9].
Serotonergic medications and cognitive behavioural
therapy (CBT) with exposure and response prevention
techniques (ERP) have been proven to be the first-line
treatments [10, 11]. However, as shown by several studies,
treatment resistance to first-line treatments is the rule ra-
ther than the exception and only about half of patients
achieve full remission from OCD symptoms [10, 12–15].
The World Health Organization [16] defined health as a
state of complete physical, mental, and social well-being
and not merely the absence of disease or infirmity. The
Positive Psychology framework [17] developed in the last
two decades has highlighted that mental health research
also needs to take into account the strengths of the patient
and his/her positive outcomes such as satisfaction with life
and well-being. This theoretical paradigm shift can allow
clinicians and policymakers to make their treatments more
effective in the long term to help patients live their lives
more meaningfully. Treatment exclusively focusing on
OCD symptom reduction may under-recognize the import-
ance of a broader set of quality-of-life and well-being out-
comes [17]. Two of these outcomes are sexual functioning
and sexual satisfaction [18], which may be associated with
improvement in OCD symptoms or recovery or, equally
importantly, with a better quality of life despite the pres-
ence of OCD symptoms. Greater sexual functioning and
sexual satisfaction may be expected to be psychological and
relational strengths which can help the person live better
despite OCD.
Sexual dysfunction and sexual satisfaction
Sexuality is one of the facets of quality of life and well-
being [19]. A variety of cross-sectional and prospective
studies support the view that sexual activity significantly
affects overall well-being for both men and women [20–
22]. Sexual dysfunctions are characterized by disturbances
in sexual desire and in psychophysiological changes asso-
ciated with the sexual response cycle in men and women
[1]. The DSM-5 [1] introduced eight diagnoses: delayed
ejaculation, erectile disorder, female orgasmic disorder,
female sexual interest-arousal disorder, genito-pelvic pain-
penetration disorder, male hypoactive sexual desire
disorder, and premature (early) ejaculation, in addition to
two non-specific codes (“Other Specified Sexual Dysfunc-
tion” and “Unspecified Sexual Dysfunction”). The DSM-5
also specifies substance- or medication-induced disorders,
included under Definitions of Sexual Dysfunctions That
Can Occur in Men and Women, which identify sexual
dysfunctions concerning sexual disorders clearly etiologic-
ally related to substance abuse or medication [1].
According to the Consensus Statement of the 4th Inter-
national Consultation on Sexual Medicine on the epidemi-
ology of sexual dysfunction [23], the most frequent sexual
dysfunctions in the general population are desire and
arousal dysfunctions for women and premature ejaculation
and erectile dysfunction for men. In a nationally representa-
tive sample of 1489 UK women [24], 5.8% reported recent
sexual dysfunction and 15.5% lifelong sexual dysfunction.
Hyposexual desire was the most prevalent recent and life-
long sexual complaint (21.4% and 17.3%, respectively).
Sexual satisfaction is an important ingredient of human
sexuality and is considered to be the last stage of the sex-
ual response cycle [25]. There are a number of definitions
of sexual satisfaction [26]. It is generally defined as the de-
gree to which an individual is satisfied or happy with the
sexual aspect of his or her relationship [27]. One of the
most accepted definitions was suggested by Lawrance and
Byers [28], who defined it as “an affective response arising
from one’s subjective evaluation of the positive and nega-
tive dimensions associated with one’s sexual relationship”
(p. 268). Sexual satisfaction is associated with better phys-
ical and psychological health and well-being [19, 29, 30],
with relationship satisfaction, and with better communica-
tion with one’s partner [29–31]. Some studies have found
a relationship between good sexual functioning and high
sexual satisfaction [30].
Sexual dysfunction and satisfaction in OCD
Sexuality in OCD is an under-recognized topic. One of
the first studies conducted in this field [32] showed that
about 10% of female patients with OCD reported anorgas-
mia and 22% had sexual arousal phase problems, whereas
25% of the male patients had lower sexual arousal, 12%
premature ejaculation problems and 6% erectile disorder,
with 39% of the patients displaying sexual dissatisfaction.
More recently, Thakurta and colleagues [33] reported that
sexual dysfunction affected 53.33% of a sample of females
with OCD. Orgasmic dysfunction was the most frequent
dysfunction affecting 20.51% of females, followed by
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problems of desire at 15.38%. Ghassemzadeh and col-
leagues [34] found that sexual dysfunction was present in
80.6% of women and 25% of men.
Some evidence from community and clinical research
showed that obsessive compulsive symptoms and OCD
diagnosis are associated with worse sexual functioning, a
higher prevalence of sexual dysfunctions and lower sexual
satisfaction. In a national epidemiological study, obsessive
compulsive behaviours were one of the strongest predic-
tors of female sexual dysfunction [24]. Kendurkar and
Kaur [35] showed that sexual dysfunction was more
prevalent among patients with OCD (50%) in comparison
with healthy controls (30%).
There are several reasons why patients with OCD may
have impaired sexual functioning or satisfaction. A first
one may be related to the effects of psychiatric medica-
tions [36]. Selective Serotonin Reuptake Inhibitors (SSRIs)
may especially delay ejaculation and female orgasm, but
also can cause decreased libido and erectile difficulties [37,
38]. Although SSRI-induced sexual side-effects are dose-
dependent and generally reversible, high dosages are used
in OCD treatment and sexual side-effects can sometimes
persist after treatment discontinuation [38]. According to
Balon [39], the incidence of SSRI-associated sexual dys-
function is between 30 and 50%. Another clinical aspect
which may explain a worse sexual well-being in patients
with OCD concerns the content of some symptoms in-
cluding obsessions related to contamination with diseases,
sexual/religious/moral themes, and the possibility of caus-
ing harm [40]. Other variables which may contribute to an
impaired sexual life may be a poorer physical health [41]
or unhealthy behaviours [42].
Rationale of the present study
Sexual life is a topic under-estimated by clinicians working
with OCD. In the international literature, there is no sys-
tematic review and meta-analysis about sexual dysfunction
and satisfaction in OCD. However, a quantitative sum-
mary of the evidence about sexual dysfunction and satis-
faction in OCD may have important implications in
clinical practice for several reasons. First, it may suggest to
practitioners that they investigate sexual life more thor-
oughly in treatment-seeking patients with OCD with the
aim of improving prognosis and treatment response to
OCD symptoms, and quality of life. Assessment and treat-
ment of OCD is typically focused on the reduction of clin-
ical symptoms, but little attention is dedicated to those
strengths and positive outcomes of the individual that are
not directly related to symptoms. Knowledge of sexual life
in OCD may also lead to the development of treatment
strategies specifically dedicated to sexuality, as no psycho-
therapeutic protocol is available for OCD associated with
sexual dysfunction or low sexual satisfaction. This point
appears to be important since poor intimate relations can
maintain or be a consequence of symptoms. Preliminary
research suggests that a partner’s involvement in therapy
(i.e., couple therapy targeting both OCD- and non-OCD-
related couple problems/stressors) can enhance symptom
reduction and improve couple functioning [43]. Thus, in-
timate relationships, including a satisfying sexual relation-
ship, could represent a relevant target of OCD treatment.
Another important reason to investigate sexual life in
OCD is the fact that depression symptoms are very com-
mon among patients with OCD [44]. Depression symp-
toms can be hypothesized to be a moderator of higher
sexual dysfunction and lower satisfaction as considerable
evidence suggests a significant directional association be-
tween depression and sexual dysfunction [45, 46]. Also,
some OCD symptoms, such as contamination fears or re-
ligious obsessions, and some negative emotions typically
associated with OCD, such as disgust and guilt, may have
a negative impact on sexuality [47, 48].
Interestingly, some studies showed the presence of
sexual dysfunctions independently by SSRIs and/or con-
tamination fear symptoms in female OCD patients [48].
Thus, sexual dysfunction in OCD could represent not
just an iatrogenic dimension but a relevant clinical di-
mension that need a proper assessment and treatment.
Objectives
The current paper presents a study protocol for a system-
atic review and meta-analysis aimed to summarize data
from primary studies (1) comparing the presence of sexual
dysfunction between clinical groups with OCD and non-
clinical groups, (2) investigating prevalence of each one of
the sexual dysfunctions in patients with OCD, (3) compar-
ing risk for sexual dysfunction in OCD groups with the
prevalence in control groups, (4) comparing sexual satisfac-
tion between OCD groups and non-clinical groups, and (5)
investigating moderators of sexual dysfunction in OCD
groups as compared with control groups. Gender, age,
marital status (percentage of married/cohabitant patients
with OCD in the study), OCD symptom severity and
subtypes, comorbid depressive disorders, comorbid anxiety
disorders, concurrent psychiatric medications, comorbid
general medical disease, and methodological quality of the
studies will be investigated as moderators. It was hypothe-
sized that younger age, male gender, married/cohabitant
status, lower OCD severity, lack of depressive disorders,
lack of comorbid anxiety disorders, lack of concurrent psy-
chiatric medication, and comorbid medical disease would
be associated with a lower risk of sexual dysfunction. A
summary of the hypotheses regarding the moderators and
the rationale for investigating them is provided in Table 1.
Methods/Design
The systematic review protocol and the procedure used
for meta-analysis have been presented according to the
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PRISMA-Protocol (PRISMA-P) [58] and were registered in
PROSPERO on CRD42019132264. Any amendments will
be updated on PROSPERO and documented accordingly.
Eligibility criteria
Studies will be included if (a) they are conducted on adult
clinical groups aged between 18 and 65 years old with a
current primary diagnosis of OCD; (b) OCD has been diag-
nosed through a clinical diagnosis or using a standardized
diagnostic clinician-administered interview, e.g., the Struc-
tured Clinical Interview for Axis I Disorders (SCID-I) [59]
based upon a standardized diagnostic international classifi-
cation system (e.g., any version of the DSM or the ICD) or
a validated self-report measure of OCD symptoms (i.e., the
reliability values are well-established) such as the Yale-
Brown Obsessive Compulsive Scale (Y-BOCS) [60]; (c) they
define sexual dysfunction according to a standardized diag-
nostic classification system (e.g., any version of the DSM or
the ICD) and investigate sexual dysfunction according to
the criteria provided by those systems, or investigate sexual
satisfaction; (d) they used a clinician-administered interview
or a self-report questionnaire with known psychometric
properties (i.e., reliability values) to assess sexual dysfunc-
tion or sexual satisfaction (overviews of the eligible mea-
sures of sexual dysfunction or satisfaction are presented in
Tables 2 and 3); (e) they used any type of research design;
(f) they measured the presence of any type of sexual dys-
function or focused on a specific type of sexual dysfunction;
and (g) they report the necessary data on effect sizes
(please, see the “Data pooling and meta-analysis” section
further on for effect size calculation) or the authors are will-
ing to provide the necessary data when contacted if such
data are missing in the study paper.
Studies where patients had concurrent psychosis, bipo-
lar disorders, neurological disorders, or mental retardation
will be excluded at full text review. This methodological
choice aims to allow us to analyze sexual dysfunction/sat-
isfaction in patients with OCD by excluding the biasing ef-
fects of such major psychiatric/neurological disorders
which can significantly impact sexual functioning.
No language restriction will be applied. Studies will be in-
cluded whether they used inpatients or outpatients. The
presence of concurrent treatment, either pharmacological or
psychotherapeutic, will not be an exclusion criterion. If
some of the patients are on concurrent medication, the per-
centage of those on medication will have to have been re-
ported and the type of medication specified. No restriction
on publication dates will be applied. Studies using patients
with a lifetime diagnosis of OCD or with subclinical or re-
mitted OCD symptoms will not be excluded. Studies where
patients had concurrent psychosis, bipolar disorders, neuro-
logical disorders, or mental retardation will not be excluded.
Table 1 Summary of moderators
Moderator Hypothesis Rationale and evidence for moderators
Age Younger age is hypothesized to be associated with
lower levels of and lower risk for sexual dysfunction,
higher sexual satisfaction
Systematic review and community studies showed that
younger age is associated with lower prevalence of
sexual dysfunction [48–50]
Gender Male gender is hypothesized to be associated with
lower levels of and lower risk for sexual dysfunction,
higher levels of sexual satisfaction
Observational studies in clinical samples with OCD showed
that females had higher prevalence of sexual dysfunctions
than men [34]
Married/Cohabitant status Married/cohabitant status is hypothesized to be
associated with lower levels of and lower risk for
sexual dysfunction, higher sexual satisfaction
Married/cohabitant status was found to be associated
with lower prevalence of sexual dysfunctions [50]
OCD symptom severity Higher OCD severity is hypothesized to be associated
with lower levels of and lower risk for sexual
dysfunction, higher sexual satisfaction
Systematic review showed that higher OCD was associated
with worse outcomes in a variety of quality of life domains [5]
Comorbid depressive
disorders
Lower percentage of comorbid depressive disorders
are hypothesized to be associated with lower levels
of and lower risk for sexual dysfunction, higher
sexual satisfaction
Observational studies in clinical and non-clinical samples
showed that comorbid depressive disorders and/or or
symptoms [34, 52]
Comorbid anxiety disorders Lower percentage of comorbid anxiety disorders
are hypothesized to be associated with lower levels
of and lower risk for sexual dysfunction, higher
sexual satisfaction
Observational studies showed that anxiety disorders are
associated with sexual dysfunctions and/or lower sexual
satisfaction [53, 54]
Concurrent psychiatric
medication
Lack of concurrent psychiatric medication is
hypothesized to be associated with lower levels
of and lower risk for sexual dysfunction, higher
sexual satisfaction
Longitudinal and cross-sectional studies showed that
psychiatric medication, specifically antidepressants, are
associated with higher levels and prevalence of sexual
dysfunctions [36–38]
Comorbid medical disease Comorbid medical disease is hypothesized to
be associated with lower levels of and lower
risk for sexual dysfunction, higher sexual
satisfaction
Systematic reviews showed that general medical disease
is associated with a higher prevalence of sexual
dysfunctions [54–56]
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Information sources and search procedure
The search will be conducted during the second week of
December 2019. Studies will be identified by conducting a
systematic search of electronic databases using Medical
Subject Headings (MeSH terms) and keywords related to
“Obsessive Compulsive Disorder” which will be combined
through the Boolean operator “AND” with MeSH terms
and keywords related to “Sexual Dysfunction” or “Sexual
Satisfaction”. MeSH terms were created by using the
PubMed MeSH on Demand Tool which allowed us to
identify relevant MeSH terms. The search procedure will
be conducted using the databases Scopus, PubMed,
EMBASE, PsycINFO, CINAHL, and the Cochrane Library.
An overview of the electronic search strategy is provided in
Table 4. The search based on electronic databases will be
piloted by one of the reviewers (AP) through a preliminary
search to ensure all relevant keywords have been captured.
A search will be conducted also on the following major
clinical trials registries: ISRCTN Registry, EU Clinical Trials
Register (EU-CTR), ClinicalTrials.gov, Clinical Research
Information Service (CRiS), Australian New Zealand
Clinical Trials Registry (ANZCTR), and Chinese Clinical
Trial Registry (ChiCTR).
In addition, to identify any further published or unpub-
lished studies, all the authors of the studies included will be
contacted. Reference sections of included studies will be
checked. Conference proceedings will be hand-searched
from inception for abstracts, papers, or posters presented at
the following international scientific societies relevant to re-
search on OCD: American Psychiatry Association, Ameri-
can Psychological Association, Anxiety and Depression
Association of America, Association for Behavioral and Cog-
nitive Therapies, European Association of Behavioural and
Cognitive Therapies, European Association of Psychiatry,
European Association of Psychology, British Psychological
Society, Royal College of Psychiatrists, British Association of
Behavioural and Cognitive Psychotherapy, International
Academy of Sex Research, International Obsessive Compul-
sive Disorder Foundation, International Society for Sexual
Medicine, European Society for Sexual Medicine, Sexual
Medicine Society of North America, International College of
Obsessive Compulsive Spectrum Disorders. This search will
be carried out independently by the two reviewers by acces-
sing the websites of these scientific societies. For any con-
ference abstracts/papers/posters judged as potentially
eligible, the corresponding author will be contacted to re-
quest further information to judge whether or not the work
can be included and/or further data should be requested to
perform the meta-analysis. Eligible theses and doctoral dis-
sertations will be searched and identified by the two inde-
pendent reviewers who will run the same queries using the
same keywords on the Open Access Theses and Disserta-
tions website.
The review process including study selection, data ex-
traction, and risk of bias assessment will be performed
through the software Covidence.
Selection of studies
Studies will be assessed and screened by two independent
reviewers (AP, DD) in three stages using inclusion/exclu-
sion criteria. During the first stage, studies will be assessed
independently by the reviewers with regards to inclusion
criteria after reading the title. Then, the reviewers will
meet to compare their selections. During the abstract se-
lection stage, the two reviewers will independently assess
Table 3 Sexual satisfaction measures which will be included in
the systematic review
Eligible measures to assess sexual satisfaction
Arizona Sexual Experience Scale (ASEX [61];)
Golombok Rust Inventory of Sexual Satisfaction (GRISS [73];)
Female Sexual Function Index
Hudson Index of Sexual Satisfaction [74]
Interpersonal Exchange Model of Sexual Satisfaction (IEMSS [75];)
International Index Erectile Function [66]
Pinney Sexual Satisfaction Inventory [76]
Sexual Activity Questionnaire (SAQ [69];)
Sexual Interaction Inventory [71]
Sexual Satisfaction Scale for Women (SSS-W [77];)
Whitley Sexual Satisfaction Inventory [78]
Table 4 Electronic search procedure
Electronic databases Search terms (MeSH and keywords)
MeSH:
“Obsessive Compulsive Disorder”
Keywords:
Obsessive Compulsive Disorder
Neurosis
Obsessions
Compulsions
Scopus
PubMed
EMBASE
PsycINFO
CINAHL
Cochrane Library
MeSH:
“Sexual Dysfunction”
Keywords:
Frigidity
Hypoactive Sexual Desire Disorder
Orgasmic Disorder
Psychosexual Disorders
Psychosexual Dysfunctions
Sexual Arousal Disorder
Sexual Aversion Disorder
Sexual Functioning
Sexual Disorders
MeSH:
“Sexual Satisfaction”
Keywords:
Sexual Satisfaction
Sexual behaviour
Sexual gratification
Orgasm
Sexual pleasure
Note: MeSH Medical Subject Heading
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each of the retained studies by reading the abstract and
again they will meet to compare their selections. During
both these stages (exclusion by title and by abstract), only
studies on which both reviewers are in complete agree-
ment on exclusion will be excluded. On the contrary,
studies will be retained if there is disagreement between
the reviewers on inclusion or exclusion. During the final
stage, studies will be assessed independently by the two re-
viewers by assessing the full text of the paper. Potential
discrepancies on inclusion or exclusion at this stage and
their reasons will be discussed and resolved in a meeting
with two other independent reviewers (UA, DP) to obtain
an agreed-upon number of included studies. Between-
reviewer agreement on inclusion will be calculated by the
Kappa index [79]. After this meeting, the decision regard-
ing the inclusion of the study will be made by another in-
dependent reviewer (DM) in a final meeting with the
other reviewers.
Data extraction
All information will be extracted from each of the in-
cluded studies by two independent reviewers (AP, DD)
and inserted into an Excel worksheet after an initial pilot
using three included studies. Table 5 provides informa-
tion on what will be extracted and coded from the pri-
mary studies. A third independent reviewer (DP) not
involved in the extraction process will check the correct-
ness of the data inserted in the worksheet. After data in-
sertion is completed, potential discrepancies in the data
extracted by the two reviewers will be discussed at a
meeting between the reviewers who conducted the data
extraction and the third independent reviewer.
Evaluation of study quality
The quality of each study will be independently evalu-
ated by two reviewers (AP, DD) using the Newcastle-
Ottawa Quality Assessment Scale [80]. The final decision
regarding the quality score to assign to each study will
be made by a third independent reviewer (DM) during a
meeting with the two quality assessors. This tool assigns
a maximum score of nine: four points regarding inclu-
sion criteria for cases and controls (definition of cases,
selection of cases, definition of controls, selection of
controls), two points regarding the comparability criteria
of cases and controls according to study design and stat-
istical analysis (comparability in terms of age and in
terms of gender), and three points for exposure verifica-
tion criteria of cases and controls (exposure verification,
same method of verification, no response point). Studies
scoring nine are classified as high quality, those scor-
ing seven or eight as medium quality, and those scor-
ing less than seven as low quality. Disagreement in
score attribution between the two authors will be set-
tled by discussion.
Data pooling and meta-analysis
Summary measures
If there is insufficient data for a specific outcome, only a
systematic review will be performed. Data will be pooled
from studies assessing the mean differences between
OCD groups and control groups regarding the levels of
sexual dysfunction, sexual satisfaction, and risk of sexual
dysfunction. If there is sufficient data, a random-effect
meta-analysis will be conducted using the software Com-
prehensive Meta-Analysis, CMA version 2.00 [81]. For all
the analyses, the p value will be set at 0.05. Random-
effect models assume that included studies are drawn
from populations of studies that systematically differ
from each other [81]. According to these models, effect
sizes extracted from included studies differ not only be-
cause of random error within studies (as in fixed-effect
models), but also because of true variation in effect sizes
from one study to another. Summary measures will con-
sist of effect-size indexes related to (1) levels of sexual
dysfunction, (2) levels of sexual satisfaction, and (3) risk
of sexual dysfunction in OCD groups as compared to
control groups. Effect-size indexes related to levels of
sexual dysfunction and levels of sexual satisfaction in
OCD as compared to controls will be calculated using
the following formula proposed by Cohen [82]: d =
(MCASE − MCONTROL)/SDCOMBINED, where MCASE and
MCONTROL represent the means of the OCD and control
groups, respectively, and SDCOMBINED is the combined
standard deviation. If a study does not include a control
group, an estimate of the general population mean for a
particular sexual dysfunction will be computed, based on
current prevalence studies or normative mean (and
standard deviation), and it will be compared with the ob-
served data on the OCD group extracted from the study
to generate a standardized mean difference.
Effect-size indexes related to risk of sexual dysfunction
in OCD as compared to controls will be calculated by
calculating the effect-size index based on the following
formula: Relative Risk Ratio = (A/n1)/(C/n2), where A/n1
represents the probability of sexual dysfunction in OCD
groups and C/n2 the probability of sexual dysfunction in
control groups. For each study, a mean effect-size index
will be calculated by pooling the effect-size indexes re-
lated to all sexual dysfunctions assessed by the study. In
addition, for each study, an effect-size index will also be
calculated for every single sexual dysfunction. A value
lower than 1 suggests that the incidence of sexual dys-
function is lower in OCD groups than in control groups,
while a value higher than 1 indicates that it is higher in
the OCD than in the control groups.
The score of each index will be weighted using the fol-
lowing correction formula: Wzr = 1/SE
2, where SE2zr is
the standard error of the effect-size index calculated for
each study. Using Cohen’s model, effect-size indexes
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Table 5 Information extracted from the primary studies and coding procedure
Information extracted Coding Moderator
Title of the paper Full title of the paper No
First author name First author’s last name No
Publication date Publication date of the paper No
Language of the paper Language in which the paper is written No
Publication on a peer-review journal “Yes”, “No” No
Publication type “Published on a journal”, “Conference paper”, “Thesis/doctoral dissertation” No
Country where the study was conducted Name of the country No
Participants’ inclusion criteria Quote the inclusion criteria reported in the study paper No
Participants’ exclusion criteria Quote the exclusion criteria reported in the study paper No
Total sample size in the study No
Participants with OCD Number of clinical participants with OCD No
Control participants Number of control participants No
Type of control participants “Undergraduates”, “Community individuals” No
Matched controls “Yes”, “No”.
If Yes, specify if match was made on age or gender or both
No
Age Total study mean age and standard deviation Yes
Females Total percentage of females Yes
Married/cohabitant patients Total percentage of married/cohabitant patients Yes
Employed patients Percentage of employed patients No
OCD symptom severity Mean Y-BOCS scores Yes
Research design “Cross-sectional case-control”, “Longitudinal” No
OCD diagnosis Diagnostic criteria used to establish OCD diagnosis No
Instrument(s) used to establish
OCD diagnosis
Acronym of the instrument(s) No
Instrument(s) used to assess sexual
dysfunction
Acronym of the instrument(s) No
Type of instrument(s) used to assess
sexual dysfunction
“Clinician-administered interview”, “Self-report questionnaire” No
Sexual dysfunction diagnosis Diagnostic criteria used to define sexual dysfunction No
Sexual dysfunction type Type of sexual dysfunction according to the classification system
used in the study
No
Sexual satisfaction Criteria used to define sexual satisfaction No
Instrument(s) used to assess sexual satisfaction Acronym of the instrument(s) No
Age at OCD onset Mean age at OCD onset in the study No
Duration of OCD Study mean duration of OCD symptoms in months No
Patients on concurrent psychiatric medication Percentage of patients on concurrent psychiatric medication Yes
Types of prescribed psychiatric medication “Atypical antipsychotics”, “Antidepressants”, “Anxiolytics” No
Types of antidepressants Generic name of the antidepressant type No
Types of antipsychotics Generic name of the antipsychotic type
Presence of concurrent psychotherapeutic treatment “Yes”, “No” No
Clinical population “Outpatient”, “Inpatient” No
Patients with sexual obsessions/compulsions Percentage of patients with sexual obsessions/compulsions No
Patients with contamination obsessions
and/or washing compulsions
Percentage of patients with contamination obsessions and/or
washing compulsions
No
Strategies used to recruit clinical participants Quote the strategies reported in the study paper No
Strategies used to recruit controls Quote the strategies reported in the study paper No
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greater than or equal to 0.80 are considered high, in-
dexes in the range of 0.80–0.50 moderate, and indexes
less than or equal to 0.20 low. Hedges’ correction for
small sample bias will be applied [83].
Effect sizes for each sexual dysfunction will be coded by
two independent reviewers who will code the measures
according to the system presented in Table 2, and a third
independent reviewer will have the final word if discrep-
ancy emerges.
Expert consultation
To assess whether the evidence from the meta-analysis on
sexual dysfunction/satisfaction are clinically meaningful, a
Delphi method will be followed by presenting the evidence
found through meta-analysis to a panel of five experts.
They will be selected according to the following criteria:
(a) being associate professor or higher in the field related
to this review topic (i.e., clinical psychology, sexology,
psychiatry), (b) editorial board membership for a journal
related to OCD and/or sexology, (c) having published at
least 15 papers on peer-review journals about OCD or
sexology. Experts will be contacted and invited to partici-
pate by email by one of the reviewers (DD) who will act as
moderator of the panel. The first consultation will be ded-
icated to presenting to each expert the issue addressed by
the review and the meta-analysis evidence. In a second
consultation, each expert will be asked separately the fol-
lowing two questions: (1) “Do these findings fit with your
clinical experience?” (2) “What is their strengths for clin-
ical practice with OCD patients?” After this session, the
statement of each expert will be recorded verbatim by the
moderator and sent to the other experts who will be given
time to complete or refine their statements. A last session
will be dedicated to a final comparison of the experts’ in-
put and the meta-analysis evidence by the moderator and
another reviewer (AP).
Publication bias
To assess the likelihood that effect sizes have been sub-
ject to publication bias, two procedures will be used:
Duval and Tweedie’s trim and fill procedure and a visual
inspection of the funnel plot [81]. A funnel plot is a scat-
ter plot in which the effect sizes computed from the in-
cluded studies are plotted on the horizontal axis against
an indicator of study precision, the Standardized Error,
on the vertical axis [81]. In the absence of bias, the graph
resembles a symmetrical inverted funnel because the
effect sizes derived from smaller studies scatter more
widely at the bottom of the graph, with the spread
narrowing as precision increases among larger studies. If
there is publication bias because smaller studies report-
ing no significant effect sizes remain unpublished, then
the funnel plot appears asymmetrical [81].
Inconsistency analysis
To verify heterogeneity in effect sizes, the prediction inter-
vals and the Q index will be calculated [84, 85]. The Q
index is calculated by summing the squared deviation of
each study’s effect estimate from the overall effect estimate,
while weighting the contribution of each study by its in-
verse variance [83]. In the hypothesis of homogeneity
among effect sizes, the Q statistic follows a chi-square
distribution with k − 1 degrees of freedom, k being the
number of studies.
Moderator analysis
If inconsistency between effect sizes is found, simple
regression analyses by weighted least squares will be per-
formed to investigate whether any of the following vari-
ables can moderate the effect sizes: (a) age, (b) gender,
(c) marital status (coded as the total percentage of mar-
ried/cohabitant patients), (d) OCD symptom severity
(measured by the Y-BOCS scores), (e) concurrent
Table 5 Information extracted from the primary studies and coding procedure (Continued)
Information extracted Coding Moderator
Setting where clinical participants
were recruited
Quote the setting where patients were recruited No
Measure(s) of depressive symptoms Acronym of the measure(s) No
Measure(s) of anxiety symptoms Acronym of the measure(s) No
Comorbid depressive disorders Percentage of patients with comorbid depressive disorders Yes
Comorbid anxiety disorders Percentage of patients with any comorbid anxiety disorders
(if different anxiety disorders are reported a mean percentage
of any anxiety disorders in the study is calculated)
Yes
Comorbid eating disorders Percentage of patients with comorbid eating disorders No
Comorbid personality disorders Percentage of patients with comorbid personality disorders No
Comorbid alcohol/substance
abuse/dependence
Percentage of patients with comorbid alcohol/substance
abuse/dependence
No
Comorbid general medical disease Percentage of patients with comorbid general medical disease Yes
Study methodological quality Score on the Newcastle-Ottawa Scale Yes
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psychiatric medication, (f) comorbid depressive disor-
ders, (g) comorbid anxiety disorders, (h) comorbid gen-
eral medical disease, (i) study methodological quality
coded as NOS scores.
Sensitivity analysis
To further account for inconsistency, sensitivity analyses
will be performed by calculating the effect sizes only on
studies using patients without concurrent psychiatric
medication and on those excluding patients with comor-
bid general medical disease.
Discussion
Sexuality is an important aspect of relational life and has a
key role in the quality of life and well-being [19, 21]. How-
ever, sexual functioning and sexual satisfaction are rarely
considered aspects of the life of patients with OCD in clin-
ical practice because OCD assessment and treatment typ-
ically focus on the reduction of symptoms; little attention
is dedicated to strengths and positive outcomes of individ-
uals with this condition. Studies on the general population
showed that obsessive compulsive tendencies are associ-
ated with sexual dysfunction or lower sexual satisfaction
[24]; higher prevalence of sexual dysfunctions and lower
sexual satisfaction were found in patients with OCD as
compared with community or healthy controls [35].
There is a need for a summary of the evidence about the
presence of sexual dysfunction and the degree of sexual sat-
isfaction in patients with OCD. In the literature, there is no
systematic review addressing these two points. Several rea-
sons may be considered to explain why patients with OCD
may be expected to have impaired sexual functioning or
lower satisfaction. A first point is related to the presence of
concurrent psychiatric medications [36] since SSRIs may
delay ejaculation and female orgasm and can also cause
decreased libido and erectile difficulties [37, 38].
Focusing assessment also on sexuality in OCD may im-
prove prognosis, treatment response to OCD symptoms,
and quality of life. Increased knowledge of sexuality in
OCD may suggest the introduction of treatment strategies
dedicated to sexuality. Recent research has shown that a
partner’s involvement in therapy (i.e., couple therapy tar-
geting both OCD and non-OCD related couple problems
and stressors) can enhance symptom reduction and im-
prove couple functioning [43]. Another important reason
to investigate sexual life in OCD is the fact that de-
pressive symptoms are very common among patients
with OCD [86].
This systematic review also has the strengths of inde-
pendent study selection and data extraction, a search
strategy based on the identification of published and un-
published studies and data including theses and doctoral
dissertations, and, lastly, an evaluation of the study’s
methodological quality. The sensitivity analysis of the
effect sizes which exclude studies with patients on psy-
chiatric medications or with general medical disease will
allow us to more clearly investigate the relationship be-
tween OCD and sexuality by excluding factors which
could potentially confuse the association between OCD
and sexual dysfunction/satisfaction.
Potential limitations will regard a small number of stud-
ies in the literature and the heterogeneity of the studies in
terms of the instruments used to assess sexual dysfunction
and sexual satisfaction and of the definitions used to
conceptualize sexual dysfunction. In addition, the cross-
sectional design of the studies to be included will not
allow us to draw causal conclusions about the relation be-
tween OCD and sexual dysfunction or impaired sexual
satisfaction. Another limitation of our protocol is the lack
of a focus on sexual preferences and sexual orientation
(i.e., heterosexual, homosexual, bisexual orientation). This
represents an interesting point which needs for a broader
investigation in future reviews.
Future works including randomized controlled designs
should focus on sexual functioning/satisfaction in patients
with OCD after and/or during the administration of medi-
cations. It may be interesting to explore which types of
psychiatric medications are associated with a negative/
positive sexual functioning to orient clinical practice. It
should also be investigated which patients’ characteristics
may be associated with the effects of medications (e.g.,
comorbidities, symptom subtypes, demographic factors).
The investigation of the evidence regarding sexual
functioning/satisfaction in patients with OCD may ad-
vance research on quality of life in this clinical popula-
tion. Further work should investigate whether standard
treatments for OCD, i.e., CBT, produce an improvement
in sexual well-being and whether such an improvement
correlates with an increase in the general level of quality
of life. It may be hypothesized that some recently devel-
oped treatment protocols for OCD may produce positive
effects on sexual life such as mindfulness-based inter-
ventions, since they are aimed to improve awareness of
body and internal/external experiences [87]. In addition,
future research should be dedicated to the integration of
strategies of sexual therapy in the standard treatment of
patients with OCD.
Another gap to be addressed in future research may be
the investigation of the clinical variables which might ex-
plain why an impaired sexual functioning can be observed
in patients with OCD. This gap might be investigated
through the comparison of sexual outcomes between
patients with OCD and patients with other obsessive com-
pulsive spectrum disorders involving a difficult relation
with body, such as body dysmorphic disorders or skin
picking disorders [88].
In conclusion, this is a protocol of the first systematic
review of sexual dysfunction and sexual satisfaction in
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patients with OCD. A clear summary of the evidence on
these topics may support clinical practice highlighting
the importance of the assessment of sexuality in OCD
and suggesting the use of therapeutic strategies dedi-
cated to sexuality in OCD with the aim of improving pa-
tients’ quality of life.
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